ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1506 • 2013 ACR/ARHP Annual Meeting

    Total Hip Replacement Outcomes in Ankylosing Spondylitis

    Susan M. Goodman1, Rebecca Zhu2, Wei-Ti Huang3, Mark P. Figgie4, Michael Alexiades5 and Lisa A. Mandl1, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Clinical Research, Hospital for Special Surgery, New York, NY, 3Epidemiology and Statistics, Hospital for Special Surgery, New York, NY, 4Orthopedics, Hospital for Special Surgery, New York, NY, 5Orthopaedics, Hospital for Special Surgery, New York, NY

    Background/Purpose: Historically, outcomes for total hip replacement (THR) in ankylosing spondylitis (AS) patients were poor, but contemporary outcomes are not well described. We analyzed two-year…
  • Abstract Number: 1507 • 2013 ACR/ARHP Annual Meeting

    Infection Risk in Ankylosing Spondylitis: Results From a Longitudinal Observational Cohort

    Dinny Wallis1, Arane Thavaneswaran2, Nigil Haroon1, Renise Ayearst2 and Robert D. Inman3, 1Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Toronto Western Hospital, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Long term data on infection risk in ankylosing spondylitis (AS) are sparse and derived mainly from RCTs.  Anti-TNF therapy is increasingly used in AS,…
  • Abstract Number: 1508 • 2013 ACR/ARHP Annual Meeting

    How Well Are The Assessment Of Spondyloarthritis International Society (ASAS) / Outcome Measures In Rheumatology (OMERACT) Core Outcome Sets For Ankylosing Spondylitis Implemented In Randomized Clinical Trials? A Systematic Literature Review

    Wilson Bautista-Molano1,2, Victoria Navarro-Compán1, Robert Landewé3 and Désirée van der Heijde4, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, Universidad Militar Nueva Granada, Bogotá, Colombia, 3Rheumatology, Academic Medical Center, Amsterdam, Netherlands, 4Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) has selected a core set of variables to include as standardized endpoints in clinical trials and clinical…
  • Abstract Number: 1509 • 2013 ACR/ARHP Annual Meeting

    Immunogenicity, Adalimumab Levels and Clinical Response In Ankylosing Spondylitis Patients During 24 Weeks Of Follow-Up

    Eva L. Kneepkens1, James C. Wei2, Michael T. Nurmohamed3,4, Kai-Jieh Yeo5, CY Chen6, Irene E. van der Horst-Bruinsma1,7, Desiree van der Kleij8, Theo Rispens9, Gertjan Wolbink3,9 and Charlotte L. M. Krieckaert3, 1Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 2Allergy/Immunology/Rheumatolog, Chung Shan Med Univ Hospital, Taichung, Taiwan, 3Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 4Rheumatology, VU University medical centre, Amsterdam, Netherlands, 5Division of Allergy, Immunology and Rheumatology, Chung Shan Med Univ Hospital, Taichung, Taiwan, 6Chung Shan Med Univ Hospital, Taichung, Taiwan, 7Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 8Sanquin Diagnostic Services, Amsterdam, Netherlands, 9Sanquin Research, Amsterdam, Netherlands

    Background/Purpose: Immunogenicity influences adalimumab levels and therefore clinical response in patients with rheumatic diseases. Objectives: To study the relation between clinical response, adalimumab levels and…
  • Abstract Number: 1510 • 2013 ACR/ARHP Annual Meeting

    Disease Activity In Male Smokers Has A >10-Fold Amplified Effect On Radiographic Damage In Comparison With Female NON-Smokers In Ankylosing Spondylitis

    Sofia Ramiro1,2, A.M. van Tubergen3, Robert Landewé4, Carmen Stolwijk5, Maxime Dougados6, Filip Van den Bosch7 and Désirée van der Heijde8, 1Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 2Rheumatology, Hospital Garcia de Orta, Almada, Portugal, 3Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 4Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, 5Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 6Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 7Ghent University Hospital, Ghent, Belgium, 8Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: We have shown that disease activity has an effect on radiographic progression over the long-term and that gender and symptom duration are effect modifiers.…
  • Abstract Number: 1511 • 2013 ACR/ARHP Annual Meeting

    What Impairs Balance In Ankylosing Spondylitis? Posture Or Disease Activity?

    Osman Hakan Gunduz1, Emel Ece Ozcan1, Esra Giray1 and Ilker Yagci2, 1Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey, 2Department of Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey

    Background/Purpose: To compare ankylosing spondylitis (AS) patients and healthy individuals in terms of posture and balance and to identify the factors affecting balance among patients…
  • Abstract Number: 1512 • 2013 ACR/ARHP Annual Meeting

    Smoking and Its Relationship With Clinical, Radiological and Functional Status In Patients With Ankylosing Spondylitis

    Fernando Andres Sommerfleck1, Emilce Edith Schneeberger1, Natalia Zamora1, Luis Alejandro Cayetti2 and Gustavo Citera1, 1Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina

    Background/Purpose: In recent years, smoking has been reported as an environmental risk factor that influence the course of certain diseases such as psoriasis, ulcerative colitis…
  • Abstract Number: 1514 • 2013 ACR/ARHP Annual Meeting

    Drug Survival In Patients Receiving Golimumab Treatment 2010-2013. Results From The Swedish Rheumatology Quality Register

    Saedis Saevarsdottir1, Michele Santacatterina2, Leszek Stawiarz3, Carl Turesson4, Helena Forsblad5, Lennart T.H. Jacobsson6 and Staffan Lindblad7, 1Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 2Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 3Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, 4Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 5Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 6Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 7Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
  • Abstract Number: 1515 • 2013 ACR/ARHP Annual Meeting

    Influence Of Taking Structural Lesions Into Account In Addition To Inflammatory Lesions On MRI Of The Sacroiliac Joints On The Classification Of Patients With Possible Axial Spondyloarthritis

    Rosaline van den Berg1, Manouk de Hooge1, Floris van Gaalen1, Victoria Navarro-Compán1, Monique Reijnierse2, Karen Fagerli3, Robert Landewé4,5, Maikel van Oosterhout6, Roberta Ramonda7, Tom Huizinga1 and Désirée van der Heijde1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Radiology, Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 5Rheumatology, Atrium Medical Center, Heerlen, Netherlands, 6Rheumatology, GHZ Hospital, Gouda, Netherlands, 7Rheumatology Unit, University of Padova, Padova, Italy

    Background/Purpose: The ASAS definition of a positive MRI of the sacroiliac joints (MRI-SI+) for the classification of axial spondyloarthritis (axSpA) patients includes inflammatory lesions only1,2.…
  • Abstract Number: 1516 • 2013 ACR/ARHP Annual Meeting

    Safety and Efficacy Of Etanercept In Early Non-Radiographic Axial Spondyloarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial At 24 Weeks

    Maxime Dougados1, Désirée van der Heijde2, Joachim Sieper3, Jürgen Braun4, Walter P. Maksymowych5, Gustavo Citera6, James Cheng-Chung Wei7, Jan Lenaerts8, Ronald Pedersen9, Randi Bonin10, Ehab Y. Mahgoub10, Bonnie Vlahos10 and Jack Bukowski11, 1Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Charité Universitätsmedizin Berlin, Berlin, Germany, 4Rheumazentrum Ruhrgebiet, Herne, Germany, 5Medicine, University of Alberta, Edmonton, AB, Canada, 6Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 7Institute of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, 8Reuma Instituut, Hasselt, Belgium, 9Specialty Care, Pfizer Inc, Collegeville, PA, 10Pfizer Inc, Collegeville, PA, 11Department of Specialty Care, Pfizer Inc, Collegeville, PA

    Background/Purpose: Limited data are available on the efficacy of anti-TNF agents in non-radiographic axial spondyloarthritis (nr-axSpA). The objective of this analysis is to compare the…
  • Abstract Number: 1517 • 2013 ACR/ARHP Annual Meeting

    Different Imaging Abnormalities Suggestive Of Spondyloarthritis Are Present In Early Axial Spondyloarthritis. Data From The DESIR Cohort

    Anna Moltó1, Simon Paternotte2, Désirée van der Heijde3, Pascal Claudepierre4, Martin Rudwaleit5 and Maxime Dougados6, 1Cochin Hospital, Paris- Descartes University, Paris, France, 2Rheumatology Department, Paris- Descartes University, Cochin hospital, Paris, France, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology, Paris-Est University; LIC EA4393; APHP, Henri Mondor Hospital, Creteil, France, 5Endokrinologikum, Berlin, Germany, 6Université Paris René Descartes and Hôpital Cochin, Paris, France

    Background/Purpose: Patients can fulfil the ASAS (Assessment of SpondyloArthritiS) sets of criteria with either objective evidence of sacroiliac joint damage (X-Ray) or inflammation (MRI) (“imaging”…
  • Abstract Number: 1518 • 2013 ACR/ARHP Annual Meeting

    Prevalence Of Spondylarthritis In Individuals Needing To Purchase An Orthopedic Mattress Because Of Chronic Back Pain

    Ahmet Eftal Yucel1, Muzeyyen Temel2, Muhtesem Agildere3 and Mustafa Agah Tekindal4, 1Internal Medicine-Rheumatology, Baskent University Faculty of Medicine, Ankara, Turkey, 2Internal Medicine, Baskent University Faculty of Medicine, Ankara, Turkey, 3Radiology, Baskent University Faculty of Medicine, Ankara, Turkey, 4Biostatistics, Baskent University Faculty of Medicine, Ankara, Turkey

    Background/Purpose: We hypothesize that the real prevalence of spondylarthritis (SpA) is much higher than reported in the literature. In this study, we aimed to investigate…
  • Abstract Number: 1519 • 2013 ACR/ARHP Annual Meeting

    Meeting The ACR 2010 Fibromyalgia Criteria Worsens Disease Activity and Quality Of Life In Patients With Axial Spondyloarthritis Treated With Infliximab

    Mathieu Verdet1, Clément Guillou2, Julien Michaud1, Christopher Banse1, Sandra Desouches1, Gilles Avenel3, Quentin Bréhier4, Aurélia Bisson-Vaivre1, Sophie Pouplin1 and Olivier Vittecoq5, 1Rheumatology, Rouen University Hospital, Rouen, France, 2Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, 3Rheumaotlogy, Rouen University Hospital, Rouen, France, 4Rheumatology, Le Havre Hospital, Le Havre, France, 5Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France

    Background/Purpose: Managing axial spondyloarthritis (aSpA) may be difficult because sometimes patients are not good responder to anti-TNF. We made the hypothesis that in certain patients,…
  • Abstract Number: 1520 • 2013 ACR/ARHP Annual Meeting

    Reduction Of Disease Burden On Workplace and Household Productivity In Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis, Over 48 Weeks Of Treatment With Certolizumab Pegol

    Désirée M. van der Heijde1, Jürgen Braun2, Martin Rudwaleit3, Oana Purcaru4 and Arthur Kavanaugh5, 1Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumazentrum Ruhrgebiet, Herne, Germany, 3Endokrinologikum, Berlin, Germany, 4UCB Pharma, Brussels, Belgium, 5Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA

    Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS, meeting modified New York criteria) and axSpA with no sacroiliitis on X-ray (non-radiographic axSpA, nr-axSpA). AS…
  • Abstract Number: 1492 • 2013 ACR/ARHP Annual Meeting

    Histone Deacetylase 1 But Not 2 Is Highly Expressed In The Lymphocyte Foci In The Labial Glands Of Patients With Sjogren’s Syndrome

    Juan Guo and Wei Zhou, Department of Rheumatology and Immunology, Peking University First Hospital, Beijing, China

    Background/Purpose: Sjogren’s syndrome (SS) is an autoimmune disease with abnormally infiltrating lymphocytes in exocrine glands expressing Th1 cytokines and increased incidence of lymphoma. Histone deacetylases…
  • « Previous Page
  • 1
  • …
  • 2148
  • 2149
  • 2150
  • 2151
  • 2152
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology